BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
LEAD Therapeutics presents new antibiotic with potent activity against drug resistant bacteria at the 49th ICAAC
News | 09. 15. 2009
LEAD Therapeutics
LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria. LEAD will present the new glycopeptide antibiotic, LT-29, for the first time at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). LT-29 is in preclinical development to treat serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
